{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T03:17:51Z","timestamp":1787887071875,"version":"build-2784847793"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05850-4","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T02:33:03Z","timestamp":1787884383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bioequivalence evaluation of risedronate sodium in healthy Chinese participants under fasting conditions: a randomized, open-label, single-dose, three-period, partial replicate crossover study"],"prefix":"10.1007","author":[{"given":"Ling","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8704-2347","authenticated-orcid":false,"given":"Yaping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"5850_CR1","unstructured":"AbbVie Inc (2026) ACTONEL (risedronate sodium) tablets prescribing information. Revised February 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/020835s054lbl.pdf"},{"key":"5850_CR2","unstructured":"Center for Drug Evaluation (2018) National Medical Products Administration (NMPA). The technical guideline for bioequivalence studies of highly variable drugs. https:\/\/www.cde.org.cn\/zdyz\/domesticinfopage?zdyzIdCODE=333fd2eac0928e881578082373233f8a"},{"issue":"7","key":"5850_CR3","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/aps.2015.30","volume":"36","author":"J Gu","year":"2015","unstructured":"Gu J, Wang L, Lin H et al (2015) The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data. Acta Pharmacol Sin 36(7):841\u2013846. https:\/\/doi.org\/10.1038\/aps.2015.30","journal-title":"Acta Pharmacol Sin"},{"issue":"2","key":"5850_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","volume":"18","author":"JH Lin","year":"1996","unstructured":"Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18(2):75\u201385. https:\/\/doi.org\/10.1016\/8756-3282(95)00445-9","journal-title":"Bone"},{"issue":"2","key":"5850_CR5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1023\/a:1011910517200","volume":"15","author":"DY Mitchell","year":"1998","unstructured":"Mitchell DY, Eusebio RA, Dunlap LE et al (1998) Risedronate gastrointestinal absorption is independent of site and rate of administration. Pharm Res 15(2):228\u2013232. https:\/\/doi.org\/10.1023\/a:1011910517200","journal-title":"Pharm Res"},{"issue":"4","key":"5850_CR6","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1046\/j.1365-2125.1999.00035.x","volume":"48","author":"DY Mitchell","year":"1999","unstructured":"Mitchell DY, Heise MA, Pallone KA et al (1999) The effect of dosing regimen on the pharmacokinetics of risedronate. Br J Clin Pharmacol 48(4):536\u2013542. https:\/\/doi.org\/10.1046\/j.1365-2125.1999.00035.x","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"5850_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1177\/00912700022008928","volume":"40","author":"DY Mitchell","year":"2000","unstructured":"Mitchell DY, Eusebio RA, Sacco-Gibson NA et al (2000) Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers. J Clin Pharmacol 40(3):258\u2013265. https:\/\/doi.org\/10.1177\/00912700022008928","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"5850_CR8","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1023\/a:1011024200280","volume":"18","author":"DY Mitchell","year":"2001","unstructured":"Mitchell DY, Barr WH, Eusebio RA et al (2001) Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration. Pharm Res 18(2):166\u2013170. https:\/\/doi.org\/10.1023\/a:1011024200280","journal-title":"Pharm Res"},{"issue":"9","key":"5850_CR9","first-page":"389","volume":"15","author":"WK Sietsema","year":"1989","unstructured":"Sietsema WK, Ebetino FH, Salvagno AM, Bevan JA (1989) Antiresorptive dose-response relationships across three generations of bisphosphonates. Drugs Exp Clin Res 15(9):389\u2013396","journal-title":"Drugs Exp Clin Res"},{"issue":"3","key":"5850_CR10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1055\/s-0033-1354365","volume":"64","author":"R Simanjuntak","year":"2013","unstructured":"Simanjuntak R, Setiawati E, Yunaidi DA et al (2013) Bioequivalence study of two risedronate sodium film-coated tablet formulations in healthy volunteers. Drug Res (Stuttg) 64(3):136\u2013140. https:\/\/doi.org\/10.1055\/s-0033-1354365","journal-title":"Drug Res (Stuttg)"},{"key":"5850_CR11","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-050124-040555","author":"AS S\u00f8lling","year":"2025","unstructured":"S\u00f8lling AS, Langdahl BL, Cosman F (2025) Recent advances in osteoporosis therapeutics. Annu Rev Med. https:\/\/doi.org\/10.1146\/annurev-med-050124-040555","journal-title":"Annu Rev Med"},{"issue":"1","key":"5850_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.18433\/j3z88f","volume":"15","author":"L Tothfalusi","year":"2012","unstructured":"Tothfalusi L, Endr\u00e9nyi L (2012) Sample sizes for designing bioequivalence studies for highly variable drugs. J Pharm Pharm Sci 15(1):73\u201384. https:\/\/doi.org\/10.18433\/j3z88f","journal-title":"J Pharm Pharm Sci"},{"issue":"21","key":"5850_CR13","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1056\/NEJMcp2307353","volume":"389","author":"MD Walker","year":"2023","unstructured":"Walker MD, Shane E (2023) Postmenopausal osteoporosis. N Engl J Med 389(21):1979\u20131991. https:\/\/doi.org\/10.1056\/NEJMcp2307353","journal-title":"N Engl J Med"},{"issue":"4","key":"5850_CR14","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s00198-016-3865-3","volume":"28","author":"NC Wright","year":"2016","unstructured":"Wright NC, Saag KG, Dawson-Hughes B, Khosla S, Siris ES (2016) The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the USA. Osteoporos Int 28(4):1225\u20131232. https:\/\/doi.org\/10.1007\/s00198-016-3865-3","journal-title":"Osteoporos Int"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05850-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05850-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05850-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T02:33:05Z","timestamp":1787884385000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05850-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":14,"alternative-id":["5850"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05850-4","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"26 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Huazhong University of Science and Technology drug clinical trial (Approval Number: 2020\u20130333).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all participants before the initiation of any research procedures.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All of the material is owned by the authors and no permissions are required.","order":4,"name":"Ethics","label":"Third-party material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that the research was conducted without any commercial or financial relationships that could be interpreted as a potential conflict of interest.","order":5,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}